The FDA has posted information on the Internet about the use of its authority in instances when it appears that a clinical investigator's misconduct poses ongoing risk to the safety and welfare of human subjects in a study involving human drug or biological products. For full text, see http://www.fda.gov/cber/guidelines.htm.
Crawford, Jr LM. Advisory on Clinical Holds. JAMA. 2002;288(13):1579. doi:10.1001/jama.288.13.1579-JFD20010-4-1